The possibility of US pricing reform has long been a concern for the biopharmaceutical industry, especially as it seemed to be a favorite topic for US President Donald Trump. But while 2017 seemed to be more talk than action, this year could be a different story.
The Ups and Downs Of US Drug Pricing Policy
If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.
